Skip to main content
Login
Contact
Subscribe
Search form
Search
The Decatur Daily Democrat
Home
Forms
Delivery Concerns
News
Sports
Obituaries
Classifieds
Place an Ad
Classified Display Ads
Photos
Videos
Games
Entertainment
Local Guide
Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Mirati Therapeutics
(NQ:
MRTX
)
102.62
USD
-2.18 (-2.08%)
Official Closing Price
/ Updated:
5:22 PM EST, Dec 6, 2019
/
Add to My Watchlist
View:
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
Press Releases
Related Stories
Blogs
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Intraday
1 Week
1 Month
3 Month
1 Year
Compare to:
None
S&P 500
Nasdaq
NYSE
AMEX
Russell 2000
Basic Materials
Conglomerates
Consumer Goods
Financial
Healthcare
Industrial Goods
Services
Technology
Utilities
Volume
538,900
Open
105.40
Bid (Size)
102.51 (8)
Ask (Size)
102.62 (21)
Prev. Close
104.80
Today's Range
101.57 - 109.74
52wk Range
34.39 - 111.99
Shares Outstanding
32,214,631
Dividend Yield
N/A
Performance
YTD
+129.83%
+129.83%
1 Month
+4.71%
+4.71%
3 Month
+24.09%
+24.09%
6 Month
+1.88%
+1.88%
1 Year
+162.32%
+162.32%
Top News
More News
Mirati Therapeutics Presents Data From Ongoing Clinical Trials Of Sitravatinib In Combination With Nivolumab At The SITC 34th Annual Meeting
November 09, 2019
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, today announced the presentation of initial data from its ongoing Phase 2 clinical trial of sitravatinib in...
Read More
from
PR Newswire
Mirati Therapeutics Reports Third Quarter 2019 Financial Results
November 04, 2019
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the third quarter ended September 30, 2019.
Read More
from
PR Newswire
More News
Read More
AstraZeneca CEO: Closing In On A Cancer Cure
November 22, 2019
category
AZN
,
General
,
CELG
, and 11 more.
from
Benzinga
Mirati Therapeutics Presents First Clinical Data Of Phase 1/2 Trial Of MRTX849 At The 2019 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics
October 28, 2019
from
PR Newswire
Noteworthy Friday Option Activity: MRTX, DHR, AXE
November 22, 2019
category
Stocks
from
Market News Video
Noteworthy Tuesday Option Activity: MRTX, R, GPRE
November 05, 2019
category
Stocks
from
Market News Video
3 Cancer Treatment Stocks to Buy Right Now
November 09, 2019
category
Market News
,
AMGN
,
PSNL
, and 3 more.
from
Motley Fool
Mid-Afternoon Market Update: Athenex Shares Spike; Grubhub Nosedives On Earnings Miss
October 29, 2019
category
BYND
,
GRUB
,
Earnings
, and 16 more.
from
Benzinga
Better Buy: Mirati Therapeutics vs. Amgen
November 02, 2019
category
MRTX
,
AMGN
,
Market News
, and 1 more.
from
Motley Fool
Mid-Morning Market Update: Markets Mixed; General Motors Profit Beats Views
October 29, 2019
category
Global
,
Markets
,
DBD
, and 16 more.
from
Benzinga
Can This Tiny Biotech Take Down Amgen?
October 31, 2019
category
Market News
,
AMGN
,
MRTX
from
Motley Fool
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.